Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394–424 (2018).
Lee, D. H., Kim, D., Park, Y. H., Yoon, J. & Kim, J. S. Long-term surgical outcomes in patients with hepatocellular carcinoma undergoing laparoscopic vs. open liver resection: A retrospective and propensity score-matched study. Asian J. Surg. 44 (1), 206–212 (2021).
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl. J. Med. 366 (26), 2455–2465 (2012).
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382 (20), 1894–1905 (2020).
Budhu, A. et al. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. Cell. Rep. Med. 4 (6), 101052 (2023).
Xu, X. et al. High proportion of circulating CD8+ CD28– senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy. J. Transl Med. 21 (1), 64 (2023).
Reschke, R. et al. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Int J Mol Sci. ;22(15). (2021).
Ferrara, R. et al. Circulating T-cell Immunosenescence in patients with advanced Non-small cell lung cancer treated with Single-agent PD-1/PD-L1 inhibitors or Platinum-based chemotherapy. Clin. Cancer Res. 27 (2), 492–503 (2021).
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer Institute of the united States, National cancer Institute of Canada. J. Natl. Cancer Inst. 92 (3), 205–216 (2000).
Llovet, J. M., Brú, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 19 (3), 329–338 (1999).
Zheng, Y., Wang, S., Cai, J., Ke, A. & Fan, J. The progress of immune checkpoint therapy in primary liver cancer. Biochim. Biophys. Acta Rev. Cancer. 1876 (2), 188638 (2021).
Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R. & Zhou, J. Targeted therapy for hepatocellular carcinoma. Signal. Transduct. Target. Ther. 5 (1), 146 (2020).
Conche, C. et al. Combining ferroptosis induction with MDSC Blockade renders primary tumours and metastases in liver sensitive to immune checkpoint Blockade. Gut 72 (9), 1774–1782 (2023).
Lyu, N., Yi, J. Z. & Zhao, M. Immunotherapy in older patients with hepatocellular carcinoma. Eur. J. Cancer. 162, 76–98 (2022).
Özkan, A. et al. Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review. Crit. Rev. Oncol. Hematol. 194, 104259 (2024).
Zhang, J. et al. LAMA4+ CD90+ eCAFs provide immunosuppressive microenvironment for liver cancer through induction of CD8+ T cell senescence. Cell. Commun. Signal. 23 (1), 203 (2025).
Naigeon, M. et al. Human Virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC. Sci. Adv. 9 (45), eadh0708 (2023).
Ramello, M. C. et al. Polyfunctional KLRG-1+CD57+ senescent CD4+ T cells infiltrate tumors and are expanded in peripheral blood from breast cancer patients. Front. Immunol. 12, 713132 (2021).
Zhang, L., Chen, X., Zu, S. & Lu, Y. Characteristics of Circulating adaptive immune cells in patients with colorectal cancer. Sci. Rep. 12 (1), 18166 (2022).
Wistuba-Hamprecht, K. et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur. J. Cancer. 73, 61–70 (2017).
Giunco, S. et al. Immune senescence and immune activation in elderly colorectal cancer patients. Aging (Albany NY). 11 (11), 3864–3875 (2019).
Pei, S. et al. Age-related decline in CD8+ tissue resident memory T cells compromises antitumor immunity. Nat. Aging. 4 (12), 1828–1844 (2024).
Chowdhury, R. R. et al. Human coronary plaque T cells are clonal and Cross-React to virus and self. Circ. Res. 130 (10), 1510–1530 (2022).
Tong, Z. et al. Single-Cell Multi-Omics identifies specialized cytotoxic and migratory CD8+ effector T cells in acute myocarditis. Circulation 152 (14), 1003–1022 (2025).
Carrasco, E. et al. The role of T cells in age-related diseases. Nat. Rev. Immunol. 22 (2), 97–111 (2022).
Song, M. et al. Low-Dose IFNγ induces tumor cell stemness in tumor microenvironment of Non-Small cell lung cancer. Cancer Res. 79 (14), 3737–3748 (2019).
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 Inhibition. N Engl. J. Med. 377 (25), 2500–2501 (2017).
Ang, C. et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget 10 (40), 4018–4025 (2019).
Xu, J. et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular Carcinoma, Gastric, or esophagogastric junction cancer: an Open-label, dose escalation and expansion study. Clin. Cancer Res. 25 (2), 515–523 (2019).
Shrestha, R. et al. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front. Oncol. 8, 269 (2018).
Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19 (7), 940–952 (2018).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (10088), 2492–2502 (2017).
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 Blockade. Science 357 (6349), 409–413 (2017).
Llovet, J. M., Montal, R., Sia, D. & Finn, R. S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 15 (10), 599–616 (2018).
Xu, X. et al. Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis. Med. (Baltim). 98 (2), e13923 (2019).
Zheng, Y. et al. Gut Microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J. Immunother Cancer. 7 (1), 193 (2019).
Shao, Y. Y. et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 39 (11), 2184–2189 (2019).